First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide

Study summary

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studied18F-αvβ6-BP

The study team can explain what participation involves.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 27, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Early Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Julie L. Sutcliffe, Ph.D

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Early Phase 1
Sponsor: Julie L. Sutcliffe, Ph.D
Interventions being studied: Drug: 18F-αvβ6-BP

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Metastatic or stage IV→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas
Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
Will sign the Institutional Review Board (IRB)-approved consent form
Able to remain motionless for up to 30-60 minutes per scan

Reasons someone may not be able to joinExclusion criteria

Creatinine \> 2 x upper limit of normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 x upper limit of normal
Life expectancy \< 3 months (mo)
Women who are pregnant or breast-feeding
Patients who cannot undergo PET/compute tomography (CT) scanning
Lack of availability for follow-up assessments
Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of California Davis Comprehensive Cancer CenterSacramento, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 27, 2026. Always confirm current availability with the study team.

View original record ↗